The Global Impact of Pre-eclampsia and Eclampsia
Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System, it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia
GLP-1RAs are a novel class of glucose-lowering agents that mimic the physiological actions of endogenous GLP-1 by enhancing insulin secretion, reducing glucagon release, and acting on the brain to inhibit gastrointestinal motility, thereby slowing nutrient absorption
This "healthy aging" approach is about maintaining function rather than just treating symptoms